NEW YORK (GenomeWeb) – Loxo Oncology announced today that it has formed a collaboration with Roche subsidiary Ventana Medical Systems to develop and commercialize a test to identify patients likely to respond to the cancer drug larotrectinib.

Loxo's larotrectinib — also known as LOXO-101 — is an oral inhibitor of tropomyosin receptor kinases (TRK), a family of proteins associated with cellular signaling and tumor growth. The drug is currently under phase I and II testing as a treatment for tumors with TRK fusions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.